33 results on '"Rizos, Helen"'
Search Results
2. Single-cell RNA sequencing in melanoma: what have we learned so far?
3. IFN-γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics
4. Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma
5. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
6. Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
7. Dosing of BRAF and MEK Inhibitors in Melanoma: No Point in Taking a Break
8. Benign blue naevi involving lymph nodes: A case series with accompanying molecular data and long term follow-up confirms clinical behaviour
9. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
10. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
11. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
12. Evaluation of commercial kits for purification of circulating free DNA
13. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
14. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
15. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
16. The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function
17. The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells
18. Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress
19. Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition
20. Oncogenic B-RAFV600E Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion
21. 38. Intralesional molecular heterogeneity in a BRAF-mutant BRAF inhibitor resistant melanoma: a case illustrating the challenges for personalised medicine
22. Absence of Distinguishing Senescence Traits in Human Melanocytic Nevi
23. Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition
24. Selective Loss of Wild-Type p16INK4a Expression in Human Nevi
25. Differential PAX3 functions in normal skin melanocytes and melanoma cells
26. Oncogenic B-RAFV600E Promotes Anchorage-Independent Survival of Human Melanocytes
27. IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence
28. Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors
29. p16INK4a Expression and Absence of Activated B-RAF Are Independent Predictors of Chemosensitivity in Melanoma Tumors
30. Physical and Functional Interaction of the p14ARF Tumor Suppressor with Ribosomes
31. The ARF tumour suppressor
32. Association of p14ARF with the p120E4FTranscriptional Repressor Enhances Cell Cycle Inhibition
33. Mutations in the INK4a/ARF Melanoma Susceptibility Locus Functionally Impair p14ARF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.